Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submissionProactive Investors • 01/13/25
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025GlobeNewsWire • 01/13/25
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseasesProactive Investors • 12/23/24
Candel Therapeutics rides high on promising Phase 3 data, funding boostProactive Investors • 12/19/24
Candel Therapeutics raises $92M in public offering following prostate cancer trial successProactive Investors • 12/16/24
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/16/24
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market SessionBenzinga • 12/13/24
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary GoalZacks Investment Research • 12/12/24
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer DrugInvestors Business Daily • 12/11/24
Candel Therapeutics reports positive Phase 3 results for CAN-2409 in localized prostate cancerProactive Investors • 12/11/24
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free SurvivalGlobeNewsWire • 12/11/24
Candel Therapeutics is pushing for a paradigm shift in cancer treatmentProactive Investors • 11/29/24
Candel Therapeutics CEO: Putting patients first is the key to reframing cancer treatmentProactive Investors • 11/22/24
Candel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps upProactive Investors • 11/14/24
Candel Therapeutics' CAN-3110 offers new hope for melanoma treatment – ICYMIProactive Investors • 11/09/24
Candel Therapeutics eyes new indication for CAN-3110 in melanoma following positive preclinical resultsProactive Investors • 11/05/24
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade GliomaGlobeNewsWire • 11/05/24
Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You ThinkSeeking Alpha • 11/01/24